The opioid partial agonist PPL‐138 reduces alcohol self‐administration in rats susceptible to post‐traumatic stress disorder
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70151 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Andrea Cippitelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, Ethanol, Analgesics, Opioid, Alcohol Drinking. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Office of the Assistant Secretary of Defense for Health Affairs.
Abstract (Originalsprache)
Background and Purpose Post‐traumatic stress disorder (PTSD) is a significant challenge in the military population and civilians exposed to danger and violence. Alcohol use disorder (AUD) and pain are common PTSD comorbidities, with a higher incidence in PTSD patients than the general population. Approved pharmacotherapies for these disorders are often ineffective and adverse effect potential limits use. No current drugs address both PTSD and alcohol use disorder. This study examines whether the opioid partial agonist PPL‐138 (BU10038) alleviates preclinical behaviours associated with PTSD such as anxiety, pain and comorbid alcohol use. Experimental Approach The single prolonged stress (SPS) model induced PTSD‐like phenotypes in male and female Sprague–Dawley rats. As PTSD afflicts only a subset of humans exposed to trauma, the effect of PPL‐138 on alcohol self‐administration was tested in SPS susceptible and resilient rat populations (defined by anxiety phenotype and escalation of alcohol‐related responses). Key Results PPL‐138 effectively reduces anxiety‐like behaviour, tactile allodynia and thermal hyperalgesia induced by SPS. It also decreases escalated alcohol consumption in male rats exhibiting comorbid anxiety‐like behaviour, leaving alcohol intake unaltered in non‐anxious phenotypes or in rats not exposed to traumatic‐like stress. The compound has a similar effect in female rats, as it reduces alcohol self‐administration selectively in anxious female rats. Conclusions and Implications Results support the efficacy of PPL‐138 to attenuate behavioural traits attributable to PTSD and alcohol consumption associated with elevated anxiety in an AUD–PTSD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA.
- Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, USA.
- Department of Biomedical Science, Charles E. Schmidt College of Medicine, Stiles-Nicholson Brain Institute, Florida Atlantic University, Jupiter, Florida, USA.
- RTI International, Research Triangle Park, North Carolina, USA.
Förderung
- Office of the Assistant Secretary of Defense for Health Affairs
Zitieren
APA
Cippitelli, A., Zhang, Y., Kealoha, K., Idriss, A., Patankar, P. S., Carper, B., Toll, L., & Standifer, K. M. (2025). The opioid partial agonist PPL‐138 reduces alcohol self‐administration in rats susceptible to post‐traumatic stress disorder. British Journal of Pharmacology. https://doi.org/10.1111/bph.70151
Vancouver
Cippitelli A, Zhang Y, Kealoha K, Idriss A, Patankar PS, Carper B, et al. The opioid partial agonist PPL‐138 reduces alcohol self‐administration in rats susceptible to post‐traumatic stress disorder. British Journal of Pharmacology. 2025. doi:10.1111/bph.70151
BibTeX
@article{Cippitelli2025,
author = {Cippitelli, Andrea and Zhang, Yong and Kealoha, Kylie and Idriss, Ali and Patankar, Panini S and Carper, Benjamin and Toll, Lawrence and Standifer, Kelly M},
title = {The opioid partial agonist PPL‐138 reduces alcohol self‐administration in rats susceptible to post‐traumatic stress disorder},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70151}
}
EUVIMED